Dose escalation study to assess the safety and tolerability of incremental doses of QAB149 [indacaterol] in adults with mild-to-moderate chronic obstructive pulmonary disease (COPD)

Trial Profile

Dose escalation study to assess the safety and tolerability of incremental doses of QAB149 [indacaterol] in adults with mild-to-moderate chronic obstructive pulmonary disease (COPD)

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Oct 2011

At a glance

  • Drugs Indacaterol (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions
  • Sponsors Novartis
  • Most Recent Events

    • 24 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top